Approved by the FDA in 2013, PAM50 is a 58-gene test that describes an individual tumor by intrinsic subtype and categorizes BCA samples into one of the following subtypes: luminal A, luminal B, Her2-enriched, and basal-like (5, 16, 89). Here, ERBB2 is linked to neoplasm.